A highly efficient and tumor vascular-targeting therapeutic technique with size-expansible gadofullerene nanocrystals
Source abstract
Abstract
It has long been a dream to achieve tumor targeting therapy that can efficiently reduce the toxicity and severe side effects of conventional antitumor chemotherapeutic agents. Taking advantage of the abnormalities of tumor vasculature, we demonstrate here a new powerful tumor vascular-targeting therapeutic technique for solid cancers that applies advanced nanotechnology to cut off the nutrient supply of tumor cells by physically destroying the abnormal tumor blood vessels. Water soluble magnetic Gd@C82 nanocrystals of the chosen sizes are deliberately designed with abilities to penetrate into the leaky tumor blood vessels. By triggering the radiofrequency induced phase transition of gadofullerene nanocrystals while extravasating the tumor blood vessel, the explosive structural change of nanoparticles generates a devastating impact on abnormal tumor blood vessels, resulting in a rapid and extensive ischemia necrosis and shrinkage of the tumors. This unprecedented target-specific physiotherapy is found to work perfectly for advanced and refractory solid tumors.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Fullerene Chemistry and Applications · Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (35)
Show source-provided references
1. Nagy JA, Chang SH, Dvorak AM, Dvorak HF. Why are tumour blood vessels abnormal and why is it important to know? Br J Cancer, 2009, 100: 865–86910.1038/sj.bjc.6604929 ↗
2. Barinaga M. Designing therapies that target tumor blood vessels. Science, 1997, 275: 482–48410.1126/science.275.5299.482 ↗
3. Heath VL, Bicknell R. Anticancer strategies involving the vasculature. Nat Rev Clin Oncol, 2009, 6: 395–40410.1038/nrclinonc.2009.52 ↗
4. Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nat Rev Cancer, 2005, 5: 423–43510.1038/nrc1628 ↗
5. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science, 2005, 307: 58–6210.1126/science.1104819 ↗
6. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer, 2005, 5: 161–17110.1038/nrc1566 ↗
7. Kievit FM, Zhang M. Cancer nanotheranostics: improving imaging and therapy by targeted delivery across biological barriers. Adv Mater, 2011, 23: H217–H24710.1002/adma.201102313 ↗
8. Greish K. Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines. J Drug Target, 2007, 15: 457–46410.1080/10611860701539584 ↗
9. Fang J, Nakamura H, Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev, 2011, 63: 136–15110.1016/j.addr.2010.04.009 ↗
10. Liu X, Chen Y, Li H, et al. Enhanced retention and cellular uptake of nanoparticles in tumors by controlling their aggregation behavior. ACS Nano, 2013, 7: 6244–625710.1021/nn402201w ↗
11. Thakor AS, Gambhir SS. Nanooncology: the future of cancer diagnosis and therapy. CA-Cancer J Clin, 2013, 63: 395–41810.3322/caac.21199 ↗
12. Li Y, Lin TY, Luo Y, et al. A smart and versatile theranostic nanomedicine platform based on nanoporphyrin. Nat Commun, 2014, 5: 471210.1038/ncomms5712 ↗
13. Siemann DW, Horsman MR. Vascular targeted therapies in oncology. Cell Tissue Res, 2009, 335: 241–24810.1007/s00441-008-0646-0 ↗
14. Wang M, Thanou M. Targeting nanoparticles to cancer. Pharm Res, 2010, 62: 90–99.10.1016/j.phrs.2010.03.005 ↗
15. de Bono JS, Ashworth A. Translating cancer research into targeted therapeutics. Nature, 2010, 467: 543–54910.1038/nature09339 ↗
16. Shu CY, Ma XY, Zhang JF, et al. Conjugation of a water-soluble gadolinium endohedral fulleride with an antibody as a magnetic resonance imaging contrast agent. Bioconjugate Chem, 2008, 19: 651–65510.1021/bc7002742 ↗
17. Shu C, Corwin FD, Zhang J, et al. Facile preparation of a new gadofullerene- based magnetic resonance imaging contrast agent with high 1H relaxivity. Bioconjugate Chem, 2009, 20: 1186–119310.1021/bc900051d ↗
18. Guo YG, Wan LJ, Li CJ, et al. The effects of annealing on the structures and electrical conductivities of fullerene-derived nanowires. J Mater Chem, 2004, 14: 914–91810.1039/b311449j ↗
19. Wang CR, Kai T, Tomiyama T, et al. Materials science: C66 fullerene encaging a scandium dimer. Nature, 2000, 408: 426–42710.1038/35044195 ↗
20. Wang T, Wu J, Xu W, et al. Spin divergence induced by exohedral modification: ESR study of Sc3C2@C80 fulleropyrrolidine. Angew Chem Int Ed, 2010, 49: 1786–178910.1002/anie.200906325 ↗
21. Li CJ, Guo YG, Li BS, et al. Template synthesis of Sc@C82(I) nanowires and nanotubes at room temperature. Adv Mater, 2005, 17: 71–7310.1002/adma.200400155 ↗
22. Sitharaman B, Bolskar RD, Rusakova I, Wilson LJ. Gd@C60 [C(COOH)2]10 and Gd@C60(OH)x: nanoscale aggregation studies of two metallofullerene MRI contrast agents in aqueous solution. Nano Lett, 2004, 4: 2373–237810.1021/nl0485713 ↗
23. Shu CY, Wang CR, Zhang JF, et al. Organophosphonate functionalized Gd@C82 as a magnetic resonance imaging contrast agent. Chem Mater, 2008, 20: 2106–210910.1021/cm7023982 ↗
24. Husebo LO, Sitharaman B, Furukawa K, Kato T, Wilson LJ. Fullerenols revisited as stable radical anions. J Am Chem Soc, 2004, 126: 12055–1206410.1021/ja047593o ↗
25. Zheng JP, Zhen MM, Ge JC, et al. Multifunctional gadofulleride nanoprobe for magnetic resonance imaging/fluorescent dual modality molecular imaging and free radical scavenging. Carbon, 2013, 65: 175–18010.1016/j.carbon.2013.08.011 ↗
26. Di Corato R, Béalle G, Kolosnjaj-Tabi J, et al. Combining magnetic hyperthermia and photodynamic therapy for tumor ablation with photoresponsive magnetic liposomes. ACS Nano, 2015, 9: 2904–291610.1021/nn506949t ↗
27. Tamarov KP, Osminkina LA, Zinovyev SV, et al. Radio frequency radiation-induced hyperthermia using Si nanoparticle-based sensitizers for mild cancer therapy. Sci Rep, 2014, 4: 703410.1038/srep07034 ↗
28. Chu KF, Dupuy DE. Thermal ablation of tumours: biological mechanisms and advances in therapy. Nat Rev Cancer, 2014, 14: 199–20810.1038/nrc3672 ↗
29. Moran C, Wainerdi S, Cherukuri T, et al. Size-dependent Joule heating of gold nanoparticles using capacitively coupled radiofrequency fields. Nano Res, 2009, 2: 400–40510.1007/s12274-009-9048-1 ↗
30. Gaya AM, Rustin GJS. Vascular disrupting agents: a new class of drug in cancer therapy. Clin Oncol, 2005, 17: 277–29010.1016/j.clon.2004.11.011 ↗
31. Hinnen P, Eskens FALM. Vascular disrupting agents in clinical development. Br J Cancer, 2007, 96: 1159–116510.1038/sj.bjc.6603694 ↗
32. Bhave M, Akhter N, Rosen ST. Cardiovascular toxicity of biologic agents for cancer therapy. Oncology-NY, 2014, 28: 482–490
33. Chen C, Xing G, Wang J, et al. Multihydroxylated [Gd@C82(OH)22]n nanoparticles: antineoplastic activity of high efficiency and low toxicity. Nano Lett, 2005, 5: 2050–205710.1021/nl051624b ↗
34. Yang D, Zhao Y, Guo H, et al. [Gd@C82(OH)22]n nanoparticles induce dendritic cell maturation and activate Th1 immune responses. ACS Nano, 2010, 4: 1178–118610.1021/nn901478z ↗
35. Kang SG, Zhou G, Yang P, et al. Molecular mechanism of pancreatic tumor metastasis inhibition by Gd@C82(OH)22 and its implication for de novo design of nanomedicine. Proc Natl Acad Sci USA, 2012, 109: 15431–1543610.1073/pnas.1204600109 ↗